Summary: Forbes covers “the positive preliminary outcomes of clinical studies by MAPS using MDMA to treat PTSD,” claiming that these results and other similar studies reveal psychedelic-assisted psychotherapy’s “potential to radically improve quality of life, up to its inevitable end.”
Originally appearing here.